Alphascript

Iovance Biotherapeutics is at the forefront of cancer treatment innovation, utilizing the human immune system's natural ability to identify and combat diverse cancer cells. Their pioneering Tumor Infiltrating Lymphocyte (TIL) therapy focuses on reinvigorating patients' own immune cells to effectively target and eliminate cancer, with ongoing clinical trials for various advanced solid tumor cancers. The company's proprietary T-cell-based immunotherapy platforms are designed to personalize treatment by targeting neoantigens unique to each tumor. With a state-of-the-art Cell Therapy Center in Philadelphia, Iovance is committed to advancing next-generation therapies for both solid tumors and blood cancers. Generated from the website